BRAF mutation leading to central nervous system rosai-dorfman disease

Timothy E. Richardson, Megan Wachsmann, Dwight Oliver, Zahidur Abedin, Diana Ye, Dennis K. Burns, Jack M. Raisanen, Benjamin M. Greenberg, Kimmo J. Hatanpaa

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Rosai–Dorfman disease (RDD) is an uncommon histiocytic proliferative disorder that can present in nodal, extranodal, or, extremely rarely, in central nervous system (CNS)-restricted form. RDD is characterized histologically as a non-Langerhans cell histiocytosis composed of atypical CD68+/S-100+/CD1a macrophages demonstrating prominent emperipolesis and effacement of the surrounding tissue. Previously thought to represent a reactive process, recent studies have raised the possibility that RDD and other histiocytic lesions, including Erdheim–Chester and Langerhans cell histiocytosis, are clonal processes linked to somatic mutations in the mitogen-activated protein (MAP) kinase pathway. Herein, we present a fatal case of RDD isolated to the CNS and used a next-generation targeted gene panel and Sanger sequencing to uncover a pathogenic deletion in the β3-αC loop of the kinase domain in exon 12 of BRAF. This mutation, previously described in melanoma and Langerhans cell histiocytosis, represents the first BRAF mutation of this kind identified in RDD. These findings support the idea that RDD is a neoplastic condition and raise the possibility that inhibitors of the MAP kinase pathway may be effective in RDD. Ann Neurol 2018;83:147–152.

Original languageEnglish (US)
Pages (from-to)147-152
Number of pages6
JournalAnnals of Neurology
Volume84
Issue number1
DOIs
StatePublished - Jul 1 2018

Fingerprint

Sinus Histiocytosis
Central Nervous System
Mutation
Langerhans Cell Histiocytosis
Mitogen-Activated Protein Kinases
Emperipolesis
Non-Langerhans-Cell Histiocytosis
Exons
Melanoma
Phosphotransferases
Macrophages

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

BRAF mutation leading to central nervous system rosai-dorfman disease. / Richardson, Timothy E.; Wachsmann, Megan; Oliver, Dwight; Abedin, Zahidur; Ye, Diana; Burns, Dennis K.; Raisanen, Jack M.; Greenberg, Benjamin M.; Hatanpaa, Kimmo J.

In: Annals of Neurology, Vol. 84, No. 1, 01.07.2018, p. 147-152.

Research output: Contribution to journalArticle

@article{c2e8bc9167b64b84bce158e13f3469c4,
title = "BRAF mutation leading to central nervous system rosai-dorfman disease",
abstract = "Rosai–Dorfman disease (RDD) is an uncommon histiocytic proliferative disorder that can present in nodal, extranodal, or, extremely rarely, in central nervous system (CNS)-restricted form. RDD is characterized histologically as a non-Langerhans cell histiocytosis composed of atypical CD68+/S-100+/CD1a– macrophages demonstrating prominent emperipolesis and effacement of the surrounding tissue. Previously thought to represent a reactive process, recent studies have raised the possibility that RDD and other histiocytic lesions, including Erdheim–Chester and Langerhans cell histiocytosis, are clonal processes linked to somatic mutations in the mitogen-activated protein (MAP) kinase pathway. Herein, we present a fatal case of RDD isolated to the CNS and used a next-generation targeted gene panel and Sanger sequencing to uncover a pathogenic deletion in the β3-αC loop of the kinase domain in exon 12 of BRAF. This mutation, previously described in melanoma and Langerhans cell histiocytosis, represents the first BRAF mutation of this kind identified in RDD. These findings support the idea that RDD is a neoplastic condition and raise the possibility that inhibitors of the MAP kinase pathway may be effective in RDD. Ann Neurol 2018;83:147–152.",
author = "Richardson, {Timothy E.} and Megan Wachsmann and Dwight Oliver and Zahidur Abedin and Diana Ye and Burns, {Dennis K.} and Raisanen, {Jack M.} and Greenberg, {Benjamin M.} and Hatanpaa, {Kimmo J.}",
year = "2018",
month = "7",
day = "1",
doi = "10.1002/ana.25281",
language = "English (US)",
volume = "84",
pages = "147--152",
journal = "Annals of Neurology",
issn = "0364-5134",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - BRAF mutation leading to central nervous system rosai-dorfman disease

AU - Richardson, Timothy E.

AU - Wachsmann, Megan

AU - Oliver, Dwight

AU - Abedin, Zahidur

AU - Ye, Diana

AU - Burns, Dennis K.

AU - Raisanen, Jack M.

AU - Greenberg, Benjamin M.

AU - Hatanpaa, Kimmo J.

PY - 2018/7/1

Y1 - 2018/7/1

N2 - Rosai–Dorfman disease (RDD) is an uncommon histiocytic proliferative disorder that can present in nodal, extranodal, or, extremely rarely, in central nervous system (CNS)-restricted form. RDD is characterized histologically as a non-Langerhans cell histiocytosis composed of atypical CD68+/S-100+/CD1a– macrophages demonstrating prominent emperipolesis and effacement of the surrounding tissue. Previously thought to represent a reactive process, recent studies have raised the possibility that RDD and other histiocytic lesions, including Erdheim–Chester and Langerhans cell histiocytosis, are clonal processes linked to somatic mutations in the mitogen-activated protein (MAP) kinase pathway. Herein, we present a fatal case of RDD isolated to the CNS and used a next-generation targeted gene panel and Sanger sequencing to uncover a pathogenic deletion in the β3-αC loop of the kinase domain in exon 12 of BRAF. This mutation, previously described in melanoma and Langerhans cell histiocytosis, represents the first BRAF mutation of this kind identified in RDD. These findings support the idea that RDD is a neoplastic condition and raise the possibility that inhibitors of the MAP kinase pathway may be effective in RDD. Ann Neurol 2018;83:147–152.

AB - Rosai–Dorfman disease (RDD) is an uncommon histiocytic proliferative disorder that can present in nodal, extranodal, or, extremely rarely, in central nervous system (CNS)-restricted form. RDD is characterized histologically as a non-Langerhans cell histiocytosis composed of atypical CD68+/S-100+/CD1a– macrophages demonstrating prominent emperipolesis and effacement of the surrounding tissue. Previously thought to represent a reactive process, recent studies have raised the possibility that RDD and other histiocytic lesions, including Erdheim–Chester and Langerhans cell histiocytosis, are clonal processes linked to somatic mutations in the mitogen-activated protein (MAP) kinase pathway. Herein, we present a fatal case of RDD isolated to the CNS and used a next-generation targeted gene panel and Sanger sequencing to uncover a pathogenic deletion in the β3-αC loop of the kinase domain in exon 12 of BRAF. This mutation, previously described in melanoma and Langerhans cell histiocytosis, represents the first BRAF mutation of this kind identified in RDD. These findings support the idea that RDD is a neoplastic condition and raise the possibility that inhibitors of the MAP kinase pathway may be effective in RDD. Ann Neurol 2018;83:147–152.

UR - http://www.scopus.com/inward/record.url?scp=85052585502&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052585502&partnerID=8YFLogxK

U2 - 10.1002/ana.25281

DO - 10.1002/ana.25281

M3 - Article

C2 - 30014527

AN - SCOPUS:85052585502

VL - 84

SP - 147

EP - 152

JO - Annals of Neurology

JF - Annals of Neurology

SN - 0364-5134

IS - 1

ER -